Cargando…

Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice

While RSV is a major cause of respiratory morbidity in infants, vaccine development is hindered by the immaturity and Th2-bias of the infant immune system and the legacy of enhanced respiratory disease (ERD) after RSV infection following immunization with formalin inactivated (FI)-RSV vaccine in ear...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Fits, Leslie, Bolder, Renske, Heemskerk-van der Meer, Marjolein, Drijver, Joke, van Polanen, Yolinda, Serroyen, Jan, Langedijk, Johannes P. M., Schuitemaker, Hanneke, Saeland, Eirikur, Zahn, Roland
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293210/ https://www.ncbi.nlm.nih.gov/pubmed/32566260 http://dx.doi.org/10.1038/s41541-020-0200-y

Ejemplares similares

Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models
por: Saeland, Eirikur, et al.
Publicado: (2023)

RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models
por: Cox, Freek, et al.
Publicado: (2023)

Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations
por: Salisch, N. C., et al.
Publicado: (2019)

A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism
por: Krarup, Anders, et al.
Publicado: (2015)

Transient opening of trimeric prefusion RSV F proteins
por: Gilman, Morgan S. A., et al.
Publicado: (2019)

Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels
por: Tiemessen, Machteld M., et al.
Publicado: (2022)

Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge
por: Cox, Freek, et al.
Publicado: (2018)

Adjuvant Selection for Influenza and RSV Prefusion Subunit Vaccines
por: Isaacs, Ariel, et al.
Publicado: (2021)

Protection of calves by a prefusion-stabilized bovine RSV F vaccine
por: Zhang, Baoshan, et al.
Publicado: (2017)

Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses
por: Bos, Rinke, et al.
Publicado: (2020)

Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine
por: Miller, Ann M., et al.
Publicado: (2023)

Lessons from the failure of the adenovector HIV vaccine
por: Blais, Marie-Eve, et al.
Publicado: (2009)

A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant Prefusion-Like Form of the F Protein Bound to Bacterium-Like Particles
por: Rigter, Alan, et al.
Publicado: (2013)

1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons
por: Ison, Michael G, et al.
Publicado: (2023)

Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform
por: Salisch, Nadine C., et al.
Publicado: (2017)

Structure-Based Design of Prefusion-Stabilized Filovirus Glycoprotein Trimers
por: Rutten, Lucy, et al.
Publicado: (2020)

Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle
por: Rainho-Tomko, Jennifer N., et al.
Publicado: (2022)

A human antibody potently neutralizes RSV by targeting the conserved hydrophobic region of prefusion F
por: Yi, Chunyan, et al.
Publicado: (2023)

An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model
por: Bockstal, Viki, et al.
Publicado: (2018)

Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease
por: van der Lubbe, Joan E. M., et al.
Publicado: (2021)

Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein
por: Harshbarger, Wayne, et al.
Publicado: (2021)

The respiratory syncytial virus (RSV) prefusion F‐protein functional antibody repertoire in adult healthy donors
por: Andreano, Emanuele, et al.
Publicado: (2021)

LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)
por: Ison, Michael G, et al.
Publicado: (2022)

Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein
por: Gilman, Morgan S. A., et al.
Publicado: (2015)

1632. Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High Neutralizing Titers in Older Adults
por: Fukushima, Yasushi, et al.
Publicado: (2023)

Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets
por: Khan, Selina, et al.
Publicado: (2022)

Alternate serotype adenovector provides long-term therapeutic gene expression in the eye
por: Hamilton, Melissa M., et al.
Publicado: (2008)

Adenovector GAD65 gene delivery into the rat trigeminal ganglion produces orofacial analgesia
por: Vit, Jean-Philippe, et al.
Publicado: (2009)

2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)

Enhancing Anti-G Antibody Induction by a Live Single-Cycle Prefusion F—Expressing RSV Vaccine Improves In Vitro and In Vivo Efficacy
por: Lamichhane, Pramila, et al.
Publicado: (2022)

Prevalent levels of RSV serum neutralizing antibodies in healthy adults outside the RSV-season
por: Van Der Plas, Johan L., et al.
Publicado: (2019)

Biodistribution and residence time of adenovector serotype 5 in normal and immunodeficient mice and rats detected with bioluminescent imaging
por: Liu, Qiang, et al.
Publicado: (2017)

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months
por: Stuart, Arabella S V, et al.
Publicado: (2022)

Architecture of the SARS coronavirus prefusion spike
por: Beniac, Daniel R, et al.
Publicado: (2006)

Global molecular diversity of RSV – the “INFORM RSV” study
por: Langedijk, Annefleur C., et al.
Publicado: (2020)

1942. Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV among US Infants
por: Hanau, Ahuva, et al.
Publicado: (2023)

High-capacity adenovector delivery of forced CRISPR-Cas9 heterodimers fosters precise chromosomal deletions in human cells
por: Tasca, Francesca, et al.
Publicado: (2023)

Decline of RSV-specific antibodies during the COVID-19 pandemic
por: den Hartog, Gerco, et al.
Publicado: (2023)

Generation of a monoclonal antibody reactive to prefusion myocytes
por: Kurisaki, Tomohiro, et al.
Publicado: (2011)

The prefusion structure of herpes simplex virus glycoprotein B
por: Vollmer, B., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ha5q5cat8vnvd2f2a9vftoirvh